Hematology-Oncology
Latest news
316 articles · 20 / page
RNA Cancer Vaccines: Revolutionary Advances Bringing Hope for 2029 Clinical Use
RNA cancer vaccines are emerging as powerful tools against hard-to-treat cancers, with breakthroughs in melanoma, pancreatic, and brain cancers showing promise for widespread clinical adoption by 2029.
FDA Clears Second Menin Inhibitor — Ziftomenib (Komzifti) for Relapsed/Refractory NPM1‑Mutated AML
Ziftomenib is FDA-approved for adults with relapsed/refractory NPM1‑mutated AML based on single‑arm KOMET‑001 data showing a 22% remission rate and manageable toxicity including differentiation syndrome; randomized trials are planned to def
DESTINY-Breast04 Consolidated: Trastuzumab Deruxtecan Improves Survival and Maintains Quality of Life in HER2‑Low Metastatic Breast Cancer
DESTINY‑Breast04 shows trastuzumab deruxtecan (T‑DXd) significantly improves progression‑free and overall survival vs physician’s choice chemotherapy in HER2‑low metastatic breast cancer, with manageable safety and preserved patient‑reporte
Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach
In a phase 1 trial, co‑infused autologous CD19- and BCMA-targeting CAR‑T cells produced 80% LLDAS/DORIS remission at 12 weeks in 15 refractory SLE patients, with manageable toxicity and evidence of eradication of autoreactive B‑cell and pla
Allogeneic HCT Rebounds, PTCy Reshapes Donor Choice, and CAR‑T Use Surges: Key Trends from the 2013–2023 CIBMTR Activity Report
CIBMTR’s 2013–2023 registry update shows a 2023 rebound in allogeneic HCT—driven by older adults—widespread adoption of post‑transplant cyclophosphamide (PTCy) across donor types, increasing mismatched donor use, and rapid expansion of comm
Donor CMV Seropositivity Tied to Worse Survival in CMV‑Seronegative AML Patients Undergoing Unrelated HCT with Post‑Transplant Cyclophosphamide
In CMV‑seronegative adult AML recipients receiving unrelated donor hematopoietic cell transplantation with PTCy, donor CMV seropositivity was associated with worse overall survival—primarily through a trend toward higher relapse—supporting
Isolated HLA‑DQB1 Mismatch and Donor Age Do Not Worsen Survival After Unrelated Donor HCT with Post‑Transplant Cyclophosphamide: A Single‑Center Analysis
A single‑center retrospective study of 988 unrelated donor HCTs with PTCy found no significant differences in survival or relapse for isolated HLA‑DQB1 mismatch, 7/8 mismatches, or older donor age; 7/8 mismatch increased severe acute GVHD a
Posttransplant Cyclophosphamide Appears to Neutralize the Adverse Effect of Older Unrelated Donor Age on Survival After Allogeneic HCT
A CIBMTR registry cohort (n=10,025) found donor age predicted worse overall survival with conventional calcineurin inhibitor prophylaxis but not with posttransplant cyclophosphamide (PTCy); attenuation was driven by reduced nonrelapse morta
Non‑conditioned Autologous Gene Therapy Reverses Bone Marrow Failure in Fanconi Anaemia‑A: FANCOLEN‑1 Phase 1/2 and Long‑Term Outcomes
The FANCOLEN‑1 trial shows that infusion of autologous FANCA‑corrected CD34+ cells without cytotoxic conditioning produced sustained engraftment and clinical improvement in a majority of treated patients with Fanconi anaemia‑A, with an acce
Breaking the Immortality of Cancer Cells: Israel’s Groundbreaking RNA-Targeting Drug
Israeli scientists have developed a novel small molecule drug that targets RNA structures maintaining cancer cell immortality, providing a promising new approach to treating hard-to-cure cancers with unparalleled precision.
Restrictive Red Blood Cell Transfusion Is Safe for Most Patients — Except in Neurocritical Care (and Some Bleeding Syndromes)
A Cochrane update (2025) of 69 randomized trials found restrictive RBC transfusion thresholds (typically Hb 7–8 g/dL) cut transfusion exposure ~42% without increasing 30‑day mortality overall, but liberal strategies improved long‑term neuro
Tailoring Transplant Conditioning and Maintenance Therapy in FLT3-ITD AML: Insights on NPM1 Mutations and Measurable Residual Disease
Posttransplant gilteritinib greatly benefits FLT3-ITD AML patients with NPM1 comutations, while myeloablative conditioning offers limited advantages over reduced-intensity conditioning in eradicating measurable residual disease.
Belantamab Mafodotin Plus Bortezomib and Dexamethasone Significantly Improves Overall Survival in Relapsed/Refractory Multiple Myeloma: Updated DREAMM-7 Results
The DREAMM-7 phase 3 trial shows that belantamab mafodotin combined with bortezomib and dexamethasone produces early, sustained, and statistically significant overall survival and deep, durable responses versus daratumumab-based therapy in
Understanding ‘Favism’: Diagnosis, Treatment, and Living with G6PD Deficiency
Favism, a hereditary enzyme deficiency causing red blood cell breakdown upon exposure to certain triggers like fava beans, is preventable with proper diagnosis and management. This article explores its clinical features, diagnosis, treatmen
CM313, a Novel Anti-CD38 Monoclonal Antibody, Demonstrates Promising Efficacy and Safety in Persistent or Chronic Primary Immune Thrombocytopenia: Insights from a Phase 2 Randomized Trial
The phase 2 trial shows that CM313 significantly improves platelet response rates and duration with manageable safety in adults with persistent or chronic primary immune thrombocytopenia.
Timely Opioid Administration in Pediatric Emergency Departments Reduces Hospitalizations for Acute Sickle Cell Pain
Prompt opioid delivery in pediatric EDs for sickle cell pain significantly lowers hospitalization rates, with the greatest benefit seen when the first dose is given within 60 minutes and the second dose within 30 minutes.
Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency
This study demonstrates the long-term effectiveness and safety of autologous gene therapy for treating ADA deficiency, showing sustained immune function and minimal adverse effects over a median follow-up of 7.5 years.
From Discovery to Breakthroughs: How Multiple Myeloma Survival Has Doubled in 20 Years
Over the past two decades, advances in therapy have doubled the median survival of multiple myeloma patients, transforming this once devastating cancer into a more manageable disease through targeted drugs and immune therapies.
Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy
Recent clinical trials report encouraging tumor shrinkage with KRAS G12D inhibitor VS-7375, significant progression-free survival benefit in soft tissue sarcoma with ozekibart, and a novel gene therapy acquisition targeting wet AMD.
Browse by specialty
Open language-specific specialty feeds and department pages.